Antihypertensive effect of repeatedly administered YM358, an angiotensin AT1-receptor antagonist, in stroke-prone spontaneously hypertensive rats

Japanese Journal of Pharmacology

Volumn 73, Issue 1, 1997, Pages 83-91

  Yamaguchi, Norikazu ^a   Fujimoto, Kazuko ^a   Fujii, Takeshi ^a   Suzuki, Takeshi ^a   Kawashima, Koichiro ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Angiotensin AT1 receptor antagonist; Antihypertensive effect; Radiotelemetry; Stroke prone spontaneously hypertensive rats; YM358

Indexed keywords

2,7 DIETHYL 5 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5H PYRAZOLO[1,5 B][1,2,4]TRIAZOLE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTERIAL PRESSURE; ARTICLE; CIRCADIAN RHYTHM; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; HEART RATE; LIGHT DARK CYCLE; LOCOMOTION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; STROKE; SYSTOLIC BLOOD PRESSURE;

EID: 0031053852     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.73.83     Document Type: Article

References (29)

1. 1 receptor antagonist. Jpn J Pharmacol 61, Supp I, 262P (1993)
2. 1) antagonist, prevents volume overload-induced cardiac hypertrophy in rats. Can J Physiol 64 Supp I, 120P (1994)
3. 1) antagonist, in experimental heart failure. Jpn J Pharmacol 67, Supp I, 124P (1995)
4. Shibasaki M, Fujimori A, Yatsu Y, Matsuda Y, Inagaki O, Okazaki T, Yanagisawa I and Takenaka T: Antihypertensive effects of YM358, a novel angiotensin II receptor antagonist. Jpn J Pharmacol 61, Supp I, 212P (1993)
5. Okazaki T, Suga A, Watanabe T, Kikuchi K, Fujimori A, Takanashi M, Shibasaki M, Inagaki O, Furuya T and Yanagisawa I: Substituted pyrazolo[1,5-b][l,2,4] triazoles as orally active angiotensin II receptor antagonists. Book of Abstracts, part 1, p. 115, 205th ACS National Meeting, Denver, Colorado (1993)
6. Tokioka T, Shibasaki M, Inagaki O, Okazaki T, Yanagisawa I, Sato N and Takenaka T: Antihypertensive effects of YM358, a novel angiotensin II receptor antagonist, in one-kidney, one clip hypertension. Jpn J Pharmacol 64, Supp I, 83P (1994)
7. Tokioka T, Shibasaki M, Fujimori A, Inagaki O, Uchida W, Okazaki T, Yanagisawa I, Sato N and Takenaka T: Difference in the vascular renin-angiotensin system in two types of renovascular hypertensive rats. Jpn J Pharmacol 67, Supp I, 264P (1994)
8. Kusayama T, Shibasaki M, Fujimori A, Inagaki O, Uchida W, Okazaki T, Yanagisawa I, Sato N and Takenaka T: Effect of YM358, an angiotensin II receptor antagonist, on anesthetized dogs in acute left ventricular failure. Jpn J Pharmacol 67, Supp I, 124P (1995)
9. Mizuno K, Tani M, Hashimoto S, Niimura S, Sanada H, Watanabe H, Ohtsuki M and Fukuchi S: Effects of losartan, a nonpeptide angiotensin II receptor antagonist, on cardiac hypertrophy and the tissue angiotensin II content in spontaneously hypertensive rats. Life Sci 51, 367-374 (1992)
10. Oddie CJ, Dilley RJ and Bobik A: Long-term angiotensin II antagonism in spontaneously hypertensive rats: Effects on blood pressure and cardiovascular amplifiers. Clin Exp Pharmacol Physiol 19, 392-395 (1992)
11. Okada M, Kobayashi M, Satoh N, Nishikibe M and Ikemoto F: Effect of chronic treatment with losartan on development of hypertension in stroke-prone spontaneously hypertensive rats (SHRSP): Comparative study with enalapril and hydralazine. Hypertens Res 16, 49-55 (1993)
12. Soltis EE: Alterations in vascular structure and function after short-term losartan treatment in spontaneously hypertensive rats, J Pharmacol Exp Ther 266, 642-646 (1993)
13. 1-receptor antagonist, in stroke-prone spontaneously hypertensive rats. Jpn J Pharmacol 69, 215-222 (1995)
14. 1 receptor antagonist, on diurnal variation in blood pressure, heart rate and locomotor activity in stroke-prone spontaneously hypertensive rats as determined by radiotelemetry. J Cardiovasc Pharmacol 27, 411-416 (1996)
15. Okamoto K, Yamori Y and Nagaoka A: Establishment of the stroke-prone spontaneously hypertensive rat (SHR). Circ Res 34-35, Suppl, 43-153 (1974)
16. Lange J, Brockaway B and Azar S: Telemetric monitoring of laboratory animals: An advanced technique that has come of : age. Lab Anim 20, 28-34 (1991)
17. Morimoto A, Nakamori T, Morimoto K, Tan N and Murakarni N: The central role of corticotrophin-releasing factor (CRF-41) in psychological stress in rats. J Physiol (Lond) 460, 221-229 (1993)
18. Kato T, Noguchi K and Sakanashi M: Evaluation of the longlasting antihypertensive action of 7-O-ethylfangchinoline. Jpn J Pharmacol 66, 35-46 (1994)
19. Wallenstein S, Zucker CL and Fleiss JL: Some statistical methods useful in circulation research. Circ Res 47, 1-9 (1980)
20. Kawashima K, Shiono K and Sokabe H: Variation of plasma and kidney renin activities among substrains of spontaneously hypertensive rats. Clin Exp Hypertens 2, 229-245 (1980)
21. Matsunaga M, Yamamoto J, Komuro T, Hara A, Yamori Y, Saito N and Ogino K: Plasma renin and vascular complications in substrains of the spontaneously hypertensive rat, with a reference to water and electrolyte balance. Jpn Cire J 40, 889 -894 (1976)
22. Wong PC, Price WA Jr, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL and Timmermans PBMWM: Hypotensive action of DuP 753, an angiotensin II antagonist, in spontaneously hypertensive rats. Nonpeptide angiotensin II receptor antagonist: X. Hypertension 15, 459-468 (1990)
23. Mizuno K, Niimura S, Tani M, Saito I, Sanada H, Takahashi M, Okazaki K, Yamaguchi M and Fukuchi S: Hypotensive activity of TCV-116, a newly developed angiotensin II receptor antagonist, in spontaneously hypertensive rats. Life Sci 51, 183-187 (1992)
24. Christen Y, Waeber B, Nussberger J, Porchet M, Borland RM, Lee RJ, Maggon K, Shum L, Timmermans PBMWM and Brunner HR: Oral administration of DuP 753, a specifie angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II. Circulation 83, 1333-1342 (1991)
25. Wong PC, Price WA Jr, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL and Timmermans PBMWM: Non- peptide angiotensin II receptor antagonists. XI. Pharmacology of EXP 3174: An active metabolite of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 255, 211-217 (1990)
26. Shibouta Y, Inada Y, Ojima M, Wada T, Noda M, Sanada T, Kubo K, Kohara Y, Naka T and Nishikawa K: Pharmacological profiles of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-l-[[2′-(1H-tetrazol-5-yl)biphenyl4-yl]methyl]-lH-benzimidazole-7- carboxylic acid (CV-11974) and its prodrug, (±)-l-(cyclohexyloxycarbonyloxy)-ethyl,2-ethoxy-l-[[2′-(1H- tetrazol-5-yl)biphenyl-4-yl]methyl]-l//-benzimidazole-7-carboxylate (TCV-116). J Pharmacol Exp Ther 266, 114-120 (1993)
27. Dickinson KEJ, Cohen RB, Skwish S, Delaney CL, Serafino RP, Poss MA, Gu Z, Ryono DE, Moreland S and Powell JR: BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP 3174. Br J Pharmacol 113, 179-189 (1994)
28. 1 receptor antagonist. J Pharmacol Exp Ther 259, 861-870 (1991)
29. Barnes NM, Costal B, Kelly ME, Murphy DA and Naylor RJ: Anxiolytic-like action of Dup 753, a nonpeptide angiotensin II receptor antagonist. Neuroreport 1, 20-21 (1990)